MedImmune: Vaccine ready to go at month's end

MedImmune, which began clinical trials for its swine flu vaccine last month, says the inhaled vaccine could be ready by the end of September. The AstraZeneca subsidiary is now waiting on the FDA to review its safety data. "There are no red flags there," Dr. Raburn Mallory told Reuters. "We think we can have 5 million doses ready to distribute at the end of September." Once it gets the greenlight, MedImmune says it will begin shipping the nasal spray vaccine to the U.S. government to fulfill its $90 million contract. Article

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.